Thu, January 11, 2018
Wed, January 10, 2018
Tue, January 9, 2018
Mon, January 8, 2018
Fri, January 5, 2018
Thu, January 4, 2018
Wed, January 3, 2018
Tue, January 2, 2018
Tue, December 26, 2017
Fri, December 22, 2017
Thu, December 21, 2017
Wed, December 20, 2017
Tue, December 19, 2017
Mon, December 18, 2017
Fri, December 15, 2017
Thu, December 14, 2017
Wed, December 13, 2017
Tue, December 12, 2017
Mon, December 11, 2017
Fri, December 8, 2017
Thu, December 7, 2017
Wed, December 6, 2017
Tue, December 5, 2017
Mon, December 4, 2017

Christopher Raymond Initiated (AKBA) at Buy and Held Target at $26 on, Dec 18th, 2017


//stocks-investing.news-articles.net/content/201 .. -buy-and-held-target-at-26-on-dec-18th-2017.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Christopher Raymond of Piper Sandler, Initiated "Akebia Therapeutics, Inc." (AKBA) at Buy and Held Target at $26 on, Dec 18th, 2017.

Christopher has made no other calls on AKBA in the last 4 months.



There are 2 other peers that have a rating on AKBA. Out of the 2 peers that are also analyzing AKBA, 0 agree with Christopher's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Christopher


  • Robert Hazlett of "BTIG" Initiated at Strong Buy and Held Target at $30 on, Thursday, December 7th, 2017
  • Difei Yang of "Mizuho" Initiated at Strong Buy and Held Target at $24 on, Thursday, October 5th, 2017

Publication Contributing Sources